HKUCTR-2864
Untitled Trial
A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals Aus Pty Ltd·Phase 1·HKU CLINICAL TRIALS REGISTRY·drugNot yet recruiting
Study focus
- Disease/Condition
- Neoplasm
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- CStone Pharmaceuticals Aus Pty Ltd
- Location
- China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- N/A
- End date
- Jan 23, 2022
ICD-10 classifications
NeoplasmsBenign neoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasm: Other specified sites
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2864
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2864 through Pure Global AI's free database. This Phase 1 trial is sponsored by CStone Pharmaceuticals Aus Pty Ltd and is currently Not yet recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.